SCHEMBL8780476

SCHEMBL8780476

CCC(C)c1cc(=O)c2ccccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.53
GAA P10253 2/20 0.53
CTSV O60911 8/20 0.49
CTSL P07711 8/20 0.49
KDM4E B2RXH2 5/20 0.46
HPGD P15428 5/20 0.46
LMNA P02545 3/20 0.46
HSD17B10 Q99714 2/20 0.46
TUBB4A P04350 1/20 0.46
TP53 P04637 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL799183 0.83 CYP1A2 (0.59) CYP1A2GAACTSVCTSLKDM4E
SCHEMBL6089085 0.80 CYP1A2 (0.56) CYP1A2GAACTSVCTSLKDM4E
SCHEMBL6088444 0.80 CYP1A2 (0.56) CYP1A2GAACTSVCTSLKDM4E
SCHEMBL14948301 0.77 CYP1A2 (0.53) CYP1A2GAACTSVCTSLKDM4E
SCHEMBL28083835 0.77 CYP1A2 (0.49) CYP1A2GAACTSVCTSLKDM4E
SCHEMBL26012345 0.76 ALOX5 (0.49) GAAKDM4EHPGDLMNATP53
SCHEMBL8298140 0.76 ALOX5 (0.49) GAAKDM4EHPGDLMNATP53
SCHEMBL20849750 0.74 LOXL2 (0.54) GAAKDM4EHPGDLMNARAB9A
SCHEMBL16254241 0.74 CTSV (0.59) CYP1A2GAACTSVCTSLKDM4E
SCHEMBL4764681 0.73 CTSV (0.67) CYP1A2GAACTSVCTSLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-03-22 US disclosed
EP-0498722-B1 Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them ROUSSEL UCLAF (FR) 1997-07-30 EP disclosed
EP-0498722-A1 Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them ROUSSEL UCLAF (FR) 1992-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071475-A1 UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY MTOR, STAT3, SLC14A1 CYP1A2 4604/4885GAA 1336/4885CTSV 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.